0000000000241858

AUTHOR

Samy Louafi

showing 3 related works from this author

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multice…

2020

Half of patients newly diagnosed with esophageal squamous cell cancer (ESCC) have metastatic disease (mESCC) and therefore a poor prognosis. Furthermore, half of patients with initial loco-regional disease present disease recurrence after surgery and/or chemoradiation. In mESCC, the recommended first-line treatment combines 5-fluorouracil and cisplatin, although this has not been validated by a phase III trial. Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy. Several molecules have been evaluated in phase I/II trials or retrospective studies (docetaxel, paclitaxel and irinotecan) but…

Oncologymedicine.medical_specialtyEsophageal NeoplasmsPaclitaxel[SDV]Life Sciences [q-bio]medicine.medical_treatmentEsophageal cancerPhases of clinical researchIrinotecan03 medical and health scienceschemistry.chemical_compoundClinical Trials Phase II as Topic0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMulticenter Studies as TopicComputingMilieux_MISCELLANEOUSRandomized Controlled Trials as Topic030304 developmental biologyCisplatin0303 health sciencesChemotherapyHepatologyPerformance statusbusiness.industryGastroenterologyEsophageal cancermedicine.disease3. Good healthSurvival RateIrinotecanPaclitaxelchemistryDocetaxel030220 oncology & carcinogenesisDisease ProgressionQuality of LifeSquamous cell cancerEsophageal Squamous Cell CarcinomaFluorouracilFranceNeoplasm Recurrence Localbusinessmedicine.drugDigestive and Liver Disease
researchProduct

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treat…

2020

Background Cancer patients are thought to have an increased risk of developing severe Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this work, predictive factors for COVID-19 severity and mortality in cancer patients were investigated. Patients and Methods In this large nationwide retro-prospective cohort study, we collected data on patients with solid tumours and COVID-19 diagnosed between March 1 and June 11, 2020. The primary endpoint was all-cause mortality and COVID-19 severity, defined as admission to an intensive care unit (ICU) and/or mechanical ventilation and/or death, was one of the secondary endpoints. Results From April 4 to June 11, 2020, 1289…

Male0301 basic medicineCancer Researchmedicine.medical_treatmentDiseaselaw.inventionCohort Studies0302 clinical medicineMechanical ventilationRisk FactorslawNeoplasmsMedicineProspective StudiesProspective cohort studyOriginal ResearchCancerIntensive care unit3. Good healthDeathOncology030220 oncology & carcinogenesisFemaleFranceImmunotherapyCohort studymedicine.medical_specialtychemotherapy. radiotherapyAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInternal medicineHumansChemotherapyIntensive care unitMortalityPandemicsAgedRetrospective StudiesChemotherapyRadiotherapySARS-CoV-2business.industryCancerCOVID-19Retrospective cohort studyOdds ratiomedicine.diseaseAged; Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; COVID-19/mortality; Cohort Studies; Female; France/epidemiology; Humans; Male; Neoplasms/mortality; Neoplasms/therapy; Neoplasms/virology; Pandemics; Prospective Studies; Retrospective Studies; Risk Factors; SARS-CoV-2/isolation & purification; COVID-19; Cancer; Chemotherapy; Death; Immunotherapy; Intensive care unit; Mechanical ventilation; Mortality; Radiotherapy030104 developmental biologybusiness
researchProduct

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic aden…

2020

Abstract Background Chemotherapy is effective in metastatic pancreatic adenocarcinoma (mPA), but new approaches are still needed to improve patients' survival and quality of life. We have previously published good efficacy and tolerability results on a sequential treatment strategy of gemcitabine followed by an intensified FOLFIRI (5FU+irinotecan) regimen. In the present study, we evaluated the same sequence but replaced gemcitabine by the new gemcitabine + nab-paclitaxel standard first-line combination. Patients and methods We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status 0–2 to alternately receive gemcitab…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyPaclitaxelPopulationLeucovorinPhases of clinical researchAdenocarcinomaNeutropeniaIrinotecanDeoxycytidineGastroenterology03 medical and health sciences0302 clinical medicineAlbuminsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasiseducationAgededucation.field_of_studyDrug Substitutionbusiness.industryMiddle Agedmedicine.diseaseGemcitabineNeoadjuvant TherapyProgression-Free SurvivalGemcitabinePancreatic NeoplasmsIrinotecanTreatment Outcome030104 developmental biologyOncologyTolerability030220 oncology & carcinogenesisDisease ProgressionFOLFIRICamptothecinFemaleFluorouracilFrancebusinessFebrile neutropeniamedicine.drugEuropean Journal of Cancer
researchProduct